Kevin O. Saunders

TL;DR: A recently developed vaccine platform, nucleoside-modified, purified mRNA encapsulated in lipid nanoparticles (mRNA-LNPs), that induces high levels of Tfh and GC B cells that are associated with long-lived and high-affinity neutralizing antibodies and durable protection.

TL;DR: It is shown that a bnAb with enhanced FcRn binding has increased gut mucosal tissue localization, which improves protection against lentiviral infection in non-human primates and suggests that modification of Fc Rn binding provides a mechanism not only to increase serum half-life but also to enhance mucosal localization that confers immune protection.

TL;DR: In this article, the authors combined cryo-electron microscopy (cryo-EM), binding, and computational analyses to study variant spikes, including one that was involved in transmission between minks and humans, and others that originated and spread in human populations.

TL;DR: It is suggested that the nucleoside-modified mRNA-LNP vaccine platform can induce robust immune responses and is a promising candidate to combat COVID-19.

TL;DR: Over the course of the study period, VRC01-lineage clades showed continuous evolution, with rates of ∼2 substitutions per 100 nucleotides per year, comparable to that of HIV-1 evolution.